Thiogenesis Announces Extension to Investor Relations Agreement

San Diego, California--(Newsfile Corp. - October 3, 2025) - **Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis** or the **Company)** a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces the extension of its investor relations agreement with Triomphe Holdings Ltd., doing business as Capital Analytica (**Consultant**) for a further 3-month term ending December 31, 2025. The original agreement was due to expire on September 30, 2025 (see the Company's news release dated September 27, 2024).

Under the extension, the Consultant shall be paid $5,000 per month for an aggregate cash consideration of $15,000. No securities are being issued in connection with the extension. All other terms of the original agreement shall remain in full force and effect and unamended. The services to be provided by the Consultant include social media consultation regarding engagement and enhancement, social sentiment reporting, social engagement reporting, discussion forum monitoring and reporting, corporate video dissemination and other related investor relations services.

The Company and the Consultant act at arm's length, and the Consultant has no present interest, directly or indirectly, in the Company or its securities. The extension and its terms are subject to acceptance by the TSX Venture Exchange.

About Thiogenesis

Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, such as cysteamine, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis' lead product candidate, TTI-0102 has an active Phase 2 clinical trial in Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS") a cleared IND for a Phase 2a clinical trial in Leigh syndrome spectrum ("LSS") and is planning a Phase 2 clinical trial in pediatric MASH.

For further information, please contact:

Brook Riggins, Director, and CFO

Email: info@thiogenesis.com
Tel.: (888) 223-9165

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.